Polyvalent nucleic acid aptamers and modulation of their activity: A focus on the thrombin binding aptamer

Pharmacology and Therapeutics

Volumn 136, Issue 2, 2012, Pages 202-215

  Musumeci, Domenica ^a   Montesarchio, Daniela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aptamers; Drug active reversal agents; Nanoparticles; Polyvalent interactions; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; APTAMER; FIBRIN; FIBRINOGEN; GOLD NANOPARTICLE; NANOMATERIAL; NANOPARTICLE; NUCLEIC ACID; OLIGONUCLEOTIDE; PEGAPTANIB; PORPHYRIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THROMBIN;

ANTIBODY SPECIFICITY; ANTICOAGULATION; ANTIGEN BINDING; BINDING AFFINITY; CHEMICAL MODIFICATION; COMBINATORIAL LIBRARY; CONJUGATE; CONJUGATION; DRUG STABILITY; ENZYME DEGRADATION; HALF LIFE TIME; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

ANIMALS; ANTICOAGULANTS; ANTIDOTES; APTAMERS, NUCLEOTIDE; HUMANS; NANOPARTICLES; THROMBIN;

EID: 84867330958     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.07.011     Document Type: Review

References (178)

1. T. Agarwal, S. Kumar, and S. Maiti Unlocking G-quadruplex: Effect of unlocked nucleic acid on G-quadruplex stability Biochimie 93 2011 1694 1700
2. D. Arosio, L. Manzoni, E.M. Araldi, and C. Scolastico Cyclic RGD functionalized gold nanoparticles for tumor targeting Bioconjug Chem 22 2011 664 672
3. A. Aviñó, C. Fàbrega, M. Tintoré, and R. Eritja Thrombin binding aptamer, more than a simple aptamer: Chemically modified derivatives and biomedical applications Curr Pharm Des 18 2012 2036 2047
4. E. Baldrich, and C.K. O'Sullivan Ability of thrombin to act as molecular chaperone, inducing formation of quadruplex structure of thrombin-binding aptamer Anal Biochem 341 2005 194 197
5. S. Bamrungsap, T. Chen, M.I. Shukoor, Z. Chen, K. Sefah, and Y. Chen Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles ACS Nano 6 2012 3974 3981
6. B. Basnar, R. Elnathan, and I. Willner Following aptamer-thrombin binding by force measurements Anal Chem 78 2006 3638 3642
7. R.C. Becker, and M.Y. Chan REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis Curr Opin Mol Ther 11 2009 707 715
8. R.C. Becker, T. Povsic, M.G. Cohen, C.P. Rusconi, and B. Sullenger Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics Thromb Haemost 103 2010 586 595
9. L.C. Bock, L.C. Griffin, J.A. Latham, E.H. Vermaas, and J.J. Toole Selection of single-stranded DNA molecules that bind and inhibit human thrombin Nature 355 1992 564 566
10. K.M. Bompiani, D.M. Monroe, F.C. Church, and B.A. Sullenger A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity J Thromb Haemost 10 2012 870 880
11. L. Bonifacio, F.C. Church, and M.B. Jarstfer Effect of locked-nucleic acid on a biologically active G-quadruplex. A structure-activity relationship of the thrombin aptamer Int J Mol Sci 9 2008 422 433
12. K.E. Borbas, C.S. Ferreira, A. Perkins, J.I. Bruce, and S. Missailidis Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer Bioconjug Chem 18 2007 1205 1212
13. L. Bromberg, D.J. Bromberg, T.A. Hatton, I. Bandín, A. Concheiro, and C. Alvarez-Lorenzo Antiviral properties of polymeric aziridine- and biguanide-modified core-shell magnetic nanoparticles Langmuir 28 2012 4548 4558
14. E.M. Bucci, M. Valente, D. Musumeci, R. Sapio, V. Anrò, and G.N. Roviello ODN-based drugs for targeting of extracellular proteins Nucleosides Nucleotides Nucleic Acids 26 2007 1047 1050
15. M.C.R. Buff, F. Schäfer, B. Wulffen, J. Müller, B. Pötzsch, and A. Heckel Dependence of aptamer activity on opposed terminal extensions: Improvement of light-regulation efficiency Nucleic Acids Res 38 2010 2111 2118
16. T. Chen, M.I. Shukoor, Y. Chen, Q. Yuan, Z. Zhu, and Z. Zhao Aptamer-conjugated nanomaterials for bioanalysis and biotechnology applications Nanoscale 3 2011 546 556
17. E.J. Cho, J.W. Lee, and A.D. Ellington Applications of aptamers as sensors Annu Rev Anal Chem (Palo Alto Calif) 2 2009 241 264
18. L.M. Chow, and T.H. Chan Novel classes of dimer antitumour drug candidates Curr Pharm Des 15 2009 659 674
19. M.G. Cohen, D.A. Purdy, J.S. Rossi, L.R. Grinfeld, S.K. Myles, and L.H. Aberle First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention Circulation 122 2010 614 622
20. T. Coppola, M. Varra, G. Oliviero, A. Galeone, G. D'Isa, and L. Mayol Synthesis, structural studies and biological properties of new TBA analogues containing an acyclic nucleotide Bioorg Med Chem 16 2008 8244 8253
21. Y. Cui, H. Ulrich, and G.P. Hess Selection of 2′-fluoro-modified RNA aptamers for alleviation of cocaine and MK-801 inhibition of the nicotinic acetylcholine receptor J Membr Biol 202 2004 137 149
22. J. D'Onofrio, L. Petraccone, E. Erra, L. Martino, G. Di Fabio, and L. De Napoli 5′-Modified G-quadruplex forming oligonucleotides endowed with anti-HIV activity: Synthesis and biophysical properties Bioconjug Chem 18 2007 1194 1204
23. J. D'Onofrio, L. Petraccone, L. Martino, G. Di Fabio, A. Iadonisi, and J. Balzarini Synthesis, biophysical characterization, and anti-HIV activity of glyco-conjugated G-quadruplex-forming oligonucleotides Bioconjug Chem 19 2008 607 616
24. E. Di Cera Thrombin as procoagulant and anticoagulant J Thromb Haemost 5 Suppl. 1 2007 196 202
25. E. Di Cera Thrombin Mol Aspects Med 29 2008 203 254
26. G. Di Fabio, J. D'Onofrio, M. Chiapparelli, B. Hoorelbeke, D. Montesarchio, and J. Balzarini Discovery of novel anti-HIV active G-quadruplex-forming oligonucleotides Chem Commun 47 2011 2363 2365
27. D.A. Di Giusto, and G.C. King Construction, stability, and activity of multivalent circular anticoagulant aptamers J Biol Chem 279 2004 46483 46489
28. C.M. Dollins, S. Nair, D. Boczkowski, J. Lee, J.M. Layzer, and E. Gilboa Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer Chem Biol 15 2008 675 682
29. M. Donalisio, M. Rusnati, A. Civra, A. Bugatti, D. Allemand, and G. Pirri Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses Antimicrob Agents Chemother 54 2010 4290 4299
30. P. Dua, S. Kim, and D.K. Lee Nucleic acid aptamers targeting cell-surface proteins Methods 54 2011 215 225
31. C.K. Dyke, S.R. Steinhubl, N.S. Kleiman, R.O. Cannon, L.G. Aberle, and M. Lin First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497
32. B.E. Eaton, L. Gold, B.J. Hicke, N. Janjic, F.M. Jucker, and D.P. Sebesta Post-SELEX combinatorial optimization of aptamers Bioorg Med Chem 5 1997 1087 1096
33. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
34. A.D. Ellington, and J.W. Szostak Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures Nature 355 1992 850 852
35. A.N. Endsley, and R.J. Ho Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells AAPS J 14 2012 225 235
36. V. Esposito, A. Galeone, L. Mayol, A. Randazzo, A. Virgilio, and A. Virno A mini-library of TBA analogues containing 3′-3′ and 5′-5′ inversion of polarity sites Nucleosides Nucleotides Nucleic Acids 26 2007 1145 1149
37. M. Famulok, J.S. Hartig, and G. Mayer Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy Chem Rev 107 2007 3715 3743
38. O.C. Farokhzad, J.J. Cheng, B.A. Teply, I. Sherifi, S. Jon, and P.W. Kantoff Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci U S A 103 2006 6315 6320
39. O.C. Farokhzad, J.M. Karp, and R. Langer Nanoparticle-aptamer bioconjugates for cancer targeting Expert Opin Drug Deliv 3 2006 311 324
40. L. Ge, G. Jin, and X. Fang Investigation of the interaction between a bivalent aptamer and thrombin by AFM Langmuir 28 2012 707 713
41. J.E. Gestwicki, C.W. Cairo, L.E. Strong, K.A. Oetjen, and L.L. Kiessling Influencing receptor-ligand binding mechanisms with multivalent ligand architecture J Am Chem Soc 124 2002 14922 14933
42. J.E. Gestwicki, L.E. Strong, and L.L. Kiessling Tuning chemotactic responses with synthetic multivalent ligands Chem Biol 7 2000 583 591
43. M.E. Gindy, and R.K. Prud'homme Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy Expert Opin Drug Deliv 6 2009 865 878
44. S. Goji, and J. Matsui Direct detection of thrombin binding to 8-bromodeoxyguanosine-modified aptamer: Effects of modification on affinity and kinetics J Nucleic Acids 2011 316079 (ID)
45. L. Gold, D. Ayers, J. Bertino, A. Bock, C. Bock, and E.N. Brody Aptamer-based multiplexed proteomic technology for biomarker discovery PLoS One 5 2010 e15004
46. L. Gold, N. Janjic, T. Jarvis, D. Schneider, J.J. Walker, and S.K. Wilcox Aptamers and the RNA world, past and present Cold Spring Harb Perspect Biol 4 2012 a003582
47. L.S. Green, D. Jellinek, C. Bell, L.A. Beebe, B.D. Feistner, and S.C. Gill Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor Chem Biol 2 1995 683 695
48. L.C. Griffin, G.F. Tidmarsh, L.C. Bock, J.J. Toole, and L.L. Leung In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 81 1993 3271 3276
49. N. Gupta, P.E. Belcher, S.A. Johnston, and C.W. Diehnelt Engineering a synthetic ligand for tumor necrosis factor-alpha Bioconjug Chem 22 2011 1473 1478
50. G.X. He, S.H. Krawczyk, S. Swaminathan, R.G. Shea, J.P. Dougherty, and T. Terhorst N2- and C8-substituted oligodeoxynucleotides with enhanced thrombin inhibitory activity in vitro and in vivo J Med Chem 41 1998 2234 2242
51. G.X. He, J.P. Williams, M.J. Postich, S. Swaminathan, R.G. Shea, and T. Terhorst In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages J Med Chem 41 1998 4224 4231
52. J.M. Healy, S.D. Lewis, M. Kurz, R.M. Boomer, K.M. Thompson, and C. Wilson Pharmacokinetics and biodistribution of novel aptamer compositions Pharm Res 21 2004 2234 2246
53. A. Heckel, M.C. Buff, M.S. Raddatz, J. Müller, B. Pötzsch, and G. Mayer An anticoagulant with light-triggered antidote activity Angew Chem Int Ed Engl 45 2006 6748 6750
54. A. Heckel, and G. Mayer Light regulation of aptamer activity: An anti-thrombin aptamer with caged thymidine nucleobases J Am Chem Soc 127 2005 822 823
55. H. Hotoda, M. Koizumi, R. Koga, M. Kaneko, K. Momota, and T. Ohmine Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3′- and 5′-end-modification, with anti-HIV-1 activity J Med Chem 41 1998 3655 3663
56. C.L. Hsu, H.T. Chang, C.T. Chen, S.C. Wei, Y.C. Shiang, and C.C. Huang Highly efficient control of thrombin activity by multivalent nanoparticles Chem Eur J 17 2011 10994 11000
57. C.L. Hsu, S.C. Wei, J.W. Jian, H.T. Chang, W.H. Chen, and C.C. Huang Highly flexible and stable aptamer-caged nanoparticles for control of thrombin activity RSC Adv 2 2012 1577 1584
58. Y.F. Huang, H.T. Chang, and W. Tan Cancer cell targeting using multiple aptamers conjugated on nanorods Anal Chem 80 2008 567 572
59. J.A. Huntington Molecular recognition mechanisms of thrombin J Thromb Haemost 3 2005 1861 1872
60. J.A. Huntington, and T.P. Baglin Targeting thrombin - rational drug design from natural mechanisms Trends Pharmacol Sci 24 2003 589 595
61. D. Jellinek, L.S. Green, C. Bell, C.K. Lynott, N. Gill, and C. Vargeese Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor Biochemistry 34 1995 11363 11372
62. T.B. Jensen, J.R. Henriksen, B.E. Rasmussen, L.M. Rasmussen, T.L. Andresen, and J. Wengel Thermodynamic and biological evaluation of a thrombin binding aptamer modified with several unlocked nucleic acid (UNA) monomers and a 2′-C-piperazino-UNA monomer Bioorg Med Chem 19 2011 4739 4745
63. W. Jiang, B.Y. Kim, J.T. Rutka, and W.C. Chan Nanoparticle-mediated cellular response is size-dependent Nat Nanotechnol 3 2008 145 150
64. A. Joachimi, G. Mayer, and J.S. Hartig A new anticoagulant-antidote pair: Control of thrombin activity by aptamers and porphyrins J Am Chem Soc 129 2007 3036 3037
65. A. Joshi, D. Vance, P. Rai, A. Thiyagarajan, and R.S. Kane The design of polyvalent therapeutics Chem Eur J 14 2008 7738 7747
66. T.L. Kamikawa, M.G. Mikolajczyk, M. Kennedy, P. Zhang, W. Wang, and D.E. Scott Nanoparticle-based biosensor for the detection of emerging pandemic influenza strains Biosens Bioelectron 26 2010 1346 1352
67. A.D. Keefe, S. Pai, and A. Ellington Aptamers as therapeutics Nat Rev Drug Discov 9 2010 537 550
68. J.A. Kelly, J. Feigon, and T.O. Yeates Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG) J Mol Biol 256 1996 417 422
69. Y. Kim, Z. Cao, and W. Tan Molecular assembly for high-performance bivalent nucleic acid inhibitor Proc Natl Acad Sci U S A 105 2008 5664 5669
70. Y. Kim, D.M. Dennis, T. Morey, L. Yang, and W. Tan Engineering dendritic aptamer assemblies as superior inhibitors of protein function Chem Asian J 5 2010 56 59
71. S.H. Krawczyk, N. Bischofberger, L.C. Griffin, V.S. Law, R.G. Shea, and S. Swaminathan Structure-activity study of oligodeoxynucleotides which inhibit thrombin Nucleosides Nucleotides 14 1995 1109 1116
72. J.H. Lee, M.V. Yigit, D. Mazumdar, and Y. Lu Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates Adv Drug Deliv Rev 62 2010 592 605
73. F. Li, G.S. Jas, G. Qin, K. Li, and Z. Li Synthesis and evaluation of bivalent, peptidomimetic antagonists of the αvβ3 integrins Bioorg Med Chem Lett 20 2010 6577 6580
74. W.X. Li, A.V. Kaplan, G.W. Grant, J.J. Toole, and L.L. Leung A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation Blood 83 1994 677 682
75. Y.J. Liao, Y.C. Shiang, C.C. Huang, and H.T. Chang Molecularly imprinted aptamers of gold nanoparticles for the enzymatic inhibition and detection of thrombin Langmuir 28 2012 8944 8951
76. P.H. Lin, R.H. Chen, C.H. Lee, Y. Chang, C.S. Chen, and W.Y. Chen Studies of the binding mechanism between aptamers and thrombin by circular dichroism, surface plasmon resonance and isothermal titration calorimetry Colloids Surf B Biointerfaces 88 2011 552 558
77. Y. Lin, D. Nieuwlandt, A. Magallanez, B. Feistner, and S.D. Jayasena High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA Nucleic Acids Res 24 1996 3407 3414
78. Y. Lin, Q. Qiu, S.C. Gill, and S.D. Jayasena Modified RNA sequence pools for in vitro selection Nucleic Acids Res 22 1994 5229 5234
79. J. López de la Osa, C. Gonzalez, R. Gargallo, M. Rueda, E. Cubero, and M. Orozco Destabilization of quadruplex DNA by 8-aminoguanine Chembiochem 7 2006 46 48
80. A. Luganini, S.F. Nicoletto, L. Pizzuto, G. Pirri, A. Giuliani, and S. Landolfo Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers Antimicrob Agents Chemother 55 2011 3231 3239
81. R.L. Lundblad, and G.C. White II The interaction of thrombin with blood platelets Platelets 16 2005 373 385
82. R.F. Macaya, P. Schultze, F.W. Smith, J.A. Roe, and J. Feigon Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution Proc Natl Acad Sci U S A 90 1993 3745 3749
83. P.R. Mallikaratchy, A. Ruggiero, J.R. Gardner, V. Kuryavyi, W.F. Maguire, and M.L. Heaney A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukaemia Nucleic Acids Res 39 2011 2458 2469
84. M. Mammen, S.K. Choi, and G.M. Whitesides Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors Angew Chem Int Ed 37 1998 2755 2794
85. K.G. Mann Biochemistry and physiology of blood coagulation Thromb Haemost 82 1999 165 174
86. V.M. Marathias, M.J. Sawicki, and P.H. Bolton 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation Nucleic Acids Res 27 1999 2860 2867
87. O. Martínez-Avila, K. Hijazi, M. Marradi, C. Clavel, C. Campion, and C. Kelly Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN Chem Eur J 15 2009 9874 9888
88. L. Martino, A. Virno, A. Randazzo, A. Virgilio, V. Esposito, and C. Giancola A new modified thrombin binding aptamer containing a 5′-5′ inversion of polarity site Nucleic Acids Res 34 2006 6653 6662
89. G. Mayer, J. Müller, T. Mack, D.F. Freitag, T. Höver, and B. Pötzsch Differential regulation of protein subdomain activity with caged bivalent ligands Chembiochem 10 2009 654 657
90. J.O. McNamara, D. Kolonias, F. Pastor, R.S. Mittler, L. Chen, and P.H. Giangrande Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice J Clin Invest 118 2008 376 386
91. C.D. Medley, S. Bamrungsap, W. Tan, and J.E. Smith Aptamer-conjugated nanoparticles for cancer cell detection Anal Chem 83 2011 727 734
92. S. Mendelboum Raviv, A. Horvath, J. Aradi, Z. Bagoly, F. Fazakas, and Z. Batta 4-Thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix J Thromb Haemost 6 2008 1764 1771
93. G. Milano, D. Musumeci, M. Gaglione, and A. Messere An alternative strategy to synthesize PNA and DNA magnetic conjugates forming nanoparticle assembly based on PNA/DNA duplexes Mol Biosyst 6 2010 553 561
94. K.N. Morris, K.B. Jensen, C.M. Julin, M. Weil, and L. Gold High affinity ligands from in vitro selection: Complex targets Proc Natl Acad Sci U S A 95 1998 2902 2907
95. J. Müller, D. Freitag, G. Mayer, and B. Pötzsch Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase J Thromb Haemost 6 2008 2105 2112
96. J. Müller, B. Wulffen, B. Pötzsch, and G. Mayer Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer Chembiochem 8 2007 2223 2226
97. D. Musumeci, E.M. Bucci, G.N. Roviello, M. Moccia, R. Sapio, and M. Valente Bent oligonucleotide duplexes as HMGB1 inhibitors: A comparative study Nucleosides Nucleotides Nucleic Acids 26 2007 1447 1450
98. D. Musumeci, E.M. Bucci, G.N. Roviello, R. Sapio, M. Valente, and M. Moccia DNA-based strategies for blocking HMGB1 cytokine activity: Design, synthesis and preliminary in vitro/in vivo assays of DNA and DNA-like duplexes Mol Biosyst 7 2011 1742 1752
99. D. Musumeci, G. Oliviero, G.N. Roviello, E.M. Bucci, and G. Piccialli G-quadruplex-forming oligonucleotide conjugated to magnetic nanoparticles: Synthesis, characterization and enzymatic stability assays Bioconjug Chem 23 2012 382 391
100. S. Nagatoishi, N. Isono, K. Tsumoto, and N. Sugimoto Loop residues of thrombin-binding DNA aptamer impact G-quadruplex stability and thrombin binding Biochimie 93 2011 1231 1238
101. S. Nagatoishi, Y. Tanaka, and K. Tsumoto Circular dichroism spectra demonstrate formation of the thrombin-binding DNA aptamer G-quadruplex under stabilizing-cation-deficient conditions Biochem Biophys Res Commun 352 2007 812 817
102. B.G. Nair, Y. Nagaoka, H. Morimoto, Y. Yoshida, T. Maekawa, and D.S. Kumar Aptamer conjugated magnetic nanoparticles as nanosurgeons Nanotechnology 21 2010 455102
103. S.R. Nallagatla, B. Heuberger, A. Haque, and C. Switzer Combinatorial synthesis of thrombin-binding aptamers containing iso-guanine J Comb Chem 11 2009 364 369
104. X. Ni, M. Castanares, A. Mukherjee, and S.E. Lupold Nucleic acid aptamers: clinical applications and promising new horizons Curr Med Chem 18 2011 4206 4214
105. S.M. Nimjee, J.R. Keys, G.A. Pitoc, G. Quick, C.P. Rusconi, and B.A. Sullenger A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery Mol Ther 14 2006 408 415
106. S.M. Nimjee, J.D. Lohrmann, H. Wang, D.J. Snyder, T.J. Cummings, and R.C. Becker Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor Mol Ther 20 2012 391 397
107. S.M. Nimjee, C.P. Rusconi, R.A. Harrington, and B.A. Sullenger The potential of aptamers as anticoagulants Trends Cardiovasc Med 15 2005 41 45
108. S.M. Nimjee, C.P. Rusconi, and B.A. Sullenger Aptamers: An emerging class of therapeutics Annu Rev Med 56 2005 555 583
109. S. Oney, R.T. Lam, K.M. Bompiani, C.M. Blake, G. Quick, and J.D. Heidel Development of universal antidotes to control aptamer activity Nat Med 15 2009 1224 1228
110. S. Oney, S.M. Nimjee, J. Layzer, N. Que-Gewirth, D. Ginsburg, and R.C. Becker Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers Oligonucleotides 17 2007 265 274
111. L.R. Paborsky, S.N. McCurdy, L.C. Griffin, J.J. Toole, and L.L. Leung The single-stranded DNA aptamer-binding site of human thrombin J Biol Chem 268 1993 20808 20811
112. K. Padmanabhan, K.P. Padmanabhan, J.D. Ferrara, J.E. Sadler, and A. Tulinsky The structure of α-thrombin inhibited by a 15-mer single-stranded DNA aptamer J Biol Chem 268 1993 17651 17654
113. K. Padmanabhan, and A. Tulinsky An ambiguous structure of a DNA 15-mer thrombin complex Acta Crystallogr Sect D 52 1996 272 282
114. B. Pagano, L. Martino, A. Randazzo, and C. Giancola Stability and binding properties of a modified thrombin binding aptamer Biophys J 94 2008 562 569
115. C.M. Paleos, D. Tsiourvas, Z. Sideratou, and L.A. Tziveleka Drug delivery using multifunctional dendrimers and hyperbranched polymers Expert Opin Drug Deliv 7 2010 1387 1398
116. I. Papp, C. Sieben, K. Ludwig, M. Roskamp, C. Böttcher, and S. Schlecht Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles Small 6 2010 2900 2906
117. I. Papp, C. Sieben, A.L. Sisson, J. Kostka, C. Böttcher, and K. Ludwig Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes Chembiochem 12 2011 887 895
118. A. Pasternak, F.J. Hernandez, L.M. Rasmussen, B. Vester, and J. Wengel Improved thrombin binding aptamer by incorporation of a single unlocked nucleic acid monomer Nucleic Acids Res 39 2011 1155 1164
119. V. Pavlov, Y. Xiao, B. Shlyahovsky, and I. Willner Aptamer-functionalized Au nanoparticles for the amplified optical detection of thrombin J Am Chem Soc 126 2004 11768 11769
120. C.G. Peng, and M.J. Damha G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-D-arabinonucleic acids (2′F-ANA) Nucleic Acids Res 35 2007 4977 4988
121. X. Peng, and J.L. Neumeyer Kappa receptor bivalent ligands Curr Top Med Chem 7 2007 363 373
122. X.-H. Peng, X. Qian, H. Mao, A.Y. Wang, Z.G. Chen, and S. Nie Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy Int J Nanomedicine 3 2008 311 321
123. Y. Phu, Z. Zhu, H. Liu, J. Zhang, J. Liu, and W. Tan Using aptamers to visualize and capture cancer cells Anal Bioanal Chem 397 2010 3225 3233
124. A. Pinto, S. Lennarz, A. Rodrigues-Correia, A. Heckel, C.K. O'Sullivan, and G. Mayer Functional detection of proteins by caged aptamers ACS Chem Biol 7 2012 360 366
125. C. Plank, O. Zelphati, and O. Mykhaylyk Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects Adv Drug Deliv Rev 63 2011 1300 1331
126. G.E. Pozmogova, M.A. Zaitseva, I.P. Smirnov, A.G. Shvachko, M.A. Murina, and V.I. Sergeenko Anticoagulant effects of thioanalogs of thrombin-binding DNA-aptamer and their stability in the plasma Bull Exp Biol Med 150 2010 180 184
127. P.A. Quiram, T.S. Hassan, and G.A. Williams Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib Retina 27 2007 851 856
128. A. Rangnekar, A.M. Zhang, S.S. Li, K.M. Bompiani, M.N. Hansen, and K.V. Gothelf Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures Nanomedicine 8 2011 673 681
129. S. Ringquist, and D. Parma Anti-L-selectin oligonucleotide ligands recognize CD62L-positive leukocytes: Binding affinity and specificity of univalent and bivalent ligands Cytometry 33 1998 394 405
130. F. Rohrbach, M.I. Fatthalla, T. Kupper, B. Pötzsch, J. Müller, and M. Petersen Chemical maturation of a bivalent aptamer by single domain variation Chembiochem 13 2012 631 634
131. D. Rotem, L. Jayasinghe, M. Salichou, and H. Bayley Protein detection by nanopores equipped with aptamers J Am Chem Soc 134 2012 2781 2787
132. J. Ruckman, L.S. Green, J. Beeson, S. Waugh, W.L. Gillette, and D.D. Henninger 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J Biol Chem 273 1998 20556 20567
133. C.P. Rusconi, J.D. Roberts, G.A. Pitoc, S.M. Nimjee, R.R. White, and G. Quick Jr. Antidote-mediated control of an anticoagulant aptamer in vivo Nat Biotechnol 22 2004 1423 1428
134. C.P. Rusconi, E. Scardino, J. Layzer, G.A. Pitoc, T.L. Ortel, and D. Monroe RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94
135. I. Russo Krauss, A. Merlino, C. Giancola, A. Randazzo, L. Mazzarella, and F. Sica Thrombin-aptamer recognition: A revealed ambiguity Nucleic Acids Res 39 2011 7858 7867
136. B. Saccà, L. Lacroix, and J.-L. Mergny The effect of chemical modifications on the thermal stability of different G-quadruplex-forming oligonucleotides Nucleic Acids Res 33 2005 1182 1192
137. S. Santulli-Marotto, S.K. Nair, C. Rusconi, B. Sullenger, and E. Gilboa Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity Cancer Res 63 2003 7483 7489
138. K.S. Schmidt, S. Borkowski, J. Kurreck, A.W. Stephens, R. Bald, and M. Hecht Application of locked nucleic acids to improve aptamer in vivo stability and targeting function Nucleic Acids Res 32 2004 5757 5765
139. P. Schultze, R.F. Macaya, and J. Feigon Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG) J Mol Biol 235 1994 1532 1547
140. D.S. Seferos, A.E. Prigodich, D.A. Giljohann, P.C. Patel, and C.A. Mirkin Polyvalent DNA nanoparticle conjugates stabilize nucleic acids Nano Lett 9 2009 308 311
141. D. Shangguan, Y. Li, Z. Tang, Z.C. Cao, H.W. Chen, and P. Mallikaratchy Aptamers evolved from live cells as effective molecular probes for cancer study Proc Natl Acad Sci U S A 103 2006 11838 11843
142. Y.-C. Shiang, C.-L. Hsu, C.-C. Huang, and H.-T. Chang Gold nanoparticles presenting hybridized self-assembled aptamers that exhibit enhanced inhibition of thrombin Angew Chem Int Ed Engl 50 2011 7660 7665
143. Y.-C. Shiang, C.-C. Huang, T.-H. Wang, C.-W. Chien, and H.-T. Chang Aptamer-Conjugated nanoparticles efficiently control the activity of thrombin Adv Funct Mater 20 2010 3175 3182
144. I. Smirnov, and R.H. Shafer Effect of loop sequence and size on DNA aptamer stability Biochemistry 39 2000 1462 1468
145. S. Sofou Surface-active liposomes for targeted cancer therapy Nanomedicine 2 2007 711 724
146. R. Stoltenburg, C. Reinemann, and B. Strehlitz SELEX - A (r)evolutionary method to generate high-affinity nucleic acid ligands Biomol Eng 24 2007 381 403
147. K. Taira, K. Abe, T. Ishibasi, K. Sato, and K. Ikebukuro Control of aptamer function using radiofrequency magnetic field J Nucleic Acids 2011 103872 (ID)
148. W. Tan, H. Wang, Y. Chen, X. Zhang, H. Zhu, and C. Yang Molecular aptamers for drug delivery Trends Biotechnol 29 2011 634 640
149. Z. Tang, P. Parekh, P. Turner, R.W. Moyer, and W. Tan Generating aptamers for recognition of virus-infected cells Clin Chem 55 2009 813 822
150. D.M. Tasset, M.F. Kubik, and W. Steiner Oligonucleotide inhibitors of human thrombin that bind distinct epitopes J Mol Biol 272 1997 688 698
151. B. Thierry Drug nanocarriers and functional nanoparticles: Applications in cancer therapy Curr Drug Deliv 6 2009 391 403
152. L. Tian, and T. Heyduk Bivalent ligands with long nanometer-scale flexible linkers Biochemistry 48 2009 264 275
153. E. Torres-Chavolla, and E.C. Alocilja Aptasensors for detection of microbial and viral pathogens Biosens Bioelectron 24 2009 3175 3182
154. M. Tsiang, A.K. Jain, K.E. Dunn, M.E. Rojas, L.L. Leung, and C.S. Gibbs Functional mapping of the surface residues of human thrombin J Biol Chem 270 1995 16854 16863
155. W.O. Tucker, K.T. Shum, and J.A. Tanner G-quadruplex DNA aptamers and their ligands: Structure, function and application Curr Pharm Des 18 2012 2014 2026
156. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
157. D. Tyssen, S.A. Henderson, A. Johnson, J. Sterjovski, K. Moore, and J. La Structure activity relationship of dendrimer microbicides with dual action antiviral activity PLoS One 5 2010 e12309
158. S. Uehara, N. Shimada, Y. Takeda, Y. Koyama, Y. Takei, and A. Ando 3′ Poly(dA)-tailed thrombin DNA aptamer to increase DNase-resistance and clotting inhibitory activity Bull Chem Soc Jpn 81 2008 1485 1491
159. D. Vance, J. Martin, S. Patke, and R.S. Kane The design of polyvalent scaffolds for targeted delivery Adv Drug Deliv Rev 61 2009 931 939
160. D. Vance, M. Shah, A. Joshi, and R.S. Kane Polyvalency: A promising strategy for drug design Biotechnol Bioeng 101 2008 429 434
161. A. Virno, A. Randazzo, C. Giancola, M. Bucci, G. Cirino, and L. Mayol A novel thrombin binding aptamer containing a G-LNA residue Bioorg Med Chem 15 2007 5710 5718
162. A.Z. Wang, V. Bagalkot, C.C. Vasilliou, F. Gu, F. Alexis, and L. Zhang Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy ChemMedChem 3 2008 1311 1315
163. J. Wang, Y. Cao, G. Chen, and G. Li Regulation of thrombin activity with a bifunctional aptamer and hemin: development of a new anticoagulant and antidote pair Chembiochem 10 2009 2171 2176
164. K.Y. Wang, S. McCurdy, R.G. Shea, S. Swaminathan, and P.H. Bolton A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA Biochemistry 32 1993 1899 1904
165. R.E. Wang, H. Wu, Y. Niu, and J. Cai Improving the stability of aptamers by chemical modification Curr Med Chem 18 2011 4126 4138
166. B. Wlotzka, S. Leva, B. Eschgfäller, J. Burmeister, F. Kleinjung, and C. Kaduk In vivo properties of an anti-GnRH Spiegelmer: An example of an oligonucleotide-based therapeutic substance class Proc Natl Acad Sci U S A 99 2002 8898 8902
167. A.S. Wolberg Thrombin generation and fibrin clot structure Blood Rev 21 2007 131 142
168. Q. Wu, M. Tsiang, and J.E. Sadler Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite J Biol Chem 267 1992 24408 24412
169. U. Wullner, I. Neef, A. Eller, M. Kleines, M.K. Tur, and S. Barth Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2 Curr Cancer Drug Targets 8 2008 554 565
170. Z. Xiao, and O.C. Farokhzad Aptamer-functionalized nanoparticles for medical applications: Challenges and opportunities ACS Nano 6 2012 3670 3676
171. Z. Xiao, E. Levy-Nissenbaum, F. Alexis, A. Lupták, B.A. Teply, and J.M. Chan Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection ACS Nano 6 2012 696 704
172. L. Yang, X. Zhang, M. Ye, J. Jiang, R. Yang, and T. Fu Aptamer-conjugated nanomaterials and their applications Adv Drug Deliv Rev 63 2011 1361 1370
173. M.V. Yigit, D. Mazumdar, and Y. Lu MRI detection of thrombin with aptamer functionalized superparamagnetic iron oxide nanoparticles Bioconjug Chem 19 2008 412 417
174. C. Yu, Y. Hu, J. Duan, W. Yuan, C. Wang, and H. Xu Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro PLoS One 6 2011 e24077
175. M. Zaitseva, D. Kaluzhny, A. Shchyolkina, O. Borisova, I. Smirnov, and G. Pozmogova Conformation and thermostability of oligonucleotide d(GGTTGGTGTGGTTGG) containing thiophosphoryl internucleotide bonds at different positions Biophys Chem 146 2010 1 6
176. E. Zavyalova, A. Golovin, R. Reshetnikov, N. Mudrik, D. Panteleyev, and G. Pavlova Novel modular DNA aptamer for human thrombin with high anticoagulant activity Curr Med Chem 18 2011 3343 3350
177. S. Zhang, A. Yekkirala, Y. Tang, and P.S. Portoghese A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors Bioorg Med Chem Lett 19 2009 6978 6980
178. J. Zhou, and J.J. Rossi Bivalent aptamers deliver the punch Chem Biol 15 2008 644 645